Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Linde PLC — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Linde PLC trades at $494.86 (market cap $226.85B). The key difference: Linde PLC is far larger — about 25.6× Kymera Therapeutics Inc. Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Linde PLC for 89 Days on average.
| KYMR | LIN | |
|---|---|---|
Market Cap | $8.87B | $226.85B |
Volume | 779,107 | 1,386,042 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $546.64 |
52-Week Low | $55.80 | $389.38 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $8.26B | $249.97B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Linde (LIN) trades at $487.35, up 0.75% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 20.43% net margins, and robust cash flow generation. Analyst consensus is overwhelmingly bullish with a $558.91 price target, representing 15% upside potential. Recent Q2 2026 results exceeded expectations with $4.50 EPS, driven by volume and pricing growth across key markets including electronics.
LIN offers quality exposure to industrial gases with AI chip contract potential, though elevated P/E of 31.75 requires sustained growth. Risks include margin pressure from higher CAPEX and sector-wide competition. The stock presents a compelling opportunity for investors seeking stable industrial exposure with growth catalysts, supported by strong institutional backing and consistent dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
